biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee

<< Previous

Bullboard Posts

Next >>

Comment by ronrydellon Jan 19, 2023 9:27pm

117 Views

Post# 35234690

RE:2-million-dollar fee

When you see how the fee is being paid...not in cash....the fee is reasonable in that their is risk involved for the fee to be effectuated at that number as it would relate to cash.

No complaints here...Also the description of the process is set forth in great detail and the deal now is being illuminated and all the vitriol can now be considered in perspective with this increased transparency.

Let's see how Monday's vote goes!

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec